We are live on !
Find out more
Farallon Capital Management Portfolio holdings
AUM
$21.7B
Turnover
63.92%
1-Year Est. Return
79.24%
This Fund
S&P 500
This Quarter Est. Return
+33.18%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$21.7B
AUM Growth
+$2.61B
(+14%)
Cap. Flow
-$3.46B
Cap. Flow % of AUM
Cap. Flow %
-15.95%
Top 10 Holdings %
Top 10 Hldgs %
62.14%
Holding
194
New
19
Increased
30
Reduced
23
Closed
105
Avg Time Held
Equity + Options
1.9
years
Top 10 Avg Time Held
Equity + Options
0.5
years
Top 20 Avg Time Held
Equity + Options
1
year
Avg Time Held Equity only
2
years
Top 10 Avg Time Held Equity only
0.8
years
Top 20 Avg Time Held Equity only
1.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$166M |
| 2 |
Roivant Sciences
ROIV
|
+$137M |
| 3 |
Immunovant
IMVT
|
+$130M |
| 4 |
BridgeBio Pharma
BBIO
|
+$96.5M |
| 5 |
Baidu
BIDU
|
+$94.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$498M |
| 2 |
Amazon
AMZN
|
+$398M |
| 3 |
Charles Schwab
SCHW
|
+$372M |
| 4 |
Aon
AON
|
+$365M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$286M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 54.84% |
| 2 | Miscellaneous | 21.83% |
| 3 | Communication Services | 8.41% |
| 4 | Technology | 5.7% |
| 5 | Financials | 3.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$817B
| $4.48B | 20.67% |
6,000,000
+3,700,000
| +161% | +$2.68B |
2025 Q3
3 quarters
|
|
2
Revolution Medicines
RVMD
$39B
| $2.54B | 11.71% |
13,550,796
-54,000
| -0.4% | -$7.89M |
2021 Q1
21 quarters
|
|
3
DELISTED
Electronic Arts
EA
| $1.62B | 7.49% |
7,919,500
+449,500
| +6% | +$91M |
2025 Q4
2 quarters
|
|
|
4
BridgeBio Pharma
BBIO
$13.3B
| $800M | 3.69% |
10,743,063
+1,377,600
| +15% | +$96.5M |
2024 Q3
7 quarters
|
|
5
Protagonist Therapeutics
PTGX
$8.7B
| $778M | 3.59% |
6,348,906
| – | – |
2017 Q4
34 quarters
|
|
6
Exelixis
EXEL
$15.5B
| $733M | 3.38% |
13,468,010
+357,000
| +3% | +$17.4M |
2018 Q3
31 quarters
|
|
7
Liquidia Corp
LQDA
$3.05B
| $667M | 3.08% |
8,365,038
-291,000
| -3% | -$15.6M |
2024 Q1
9 quarters
|
|
|
8
Amazon
AMZN
$2.83T
| $628M | 2.9% |
2,632,994
-1,585,400
| -38% | -$398M |
2025 Q2
4 quarters
|
|
9
Lantheus
LNTH
$6.52B
| $619M | 2.86% |
5,583,479
| – | – |
2023 Q1
13 quarters
|
|
10
Natera
NTRA
$57.6B
| $602M | 2.78% |
2,218,366
-989,000
| -31% | -$211M |
2021 Q2
20 quarters
|
|
11
UnitedHealth
UNH
$365B
| $528M | 2.44% |
1,270,532
-551,174
| -30% | -$204M |
2023 Q1
13 quarters
|
|
12
Thermo Fisher Scientific
TMO
$251B
| $526M | 2.43% |
1,049,185
+167,700
| +19% | +$80.5M |
2019 Q4
26 quarters
|
|
|
13
Roivant Sciences
ROIV
$25.1B
| $506M | 2.34% |
14,309,000
+4,634,000
| +48% | +$137M |
2023 Q2
12 quarters
|
|
|
14
Aon
AON
$61.5B
| $459M | 2.12% |
1,382,562
-1,130,076
| -45% | -$365M |
2024 Q1
9 quarters
|
|
|
15
Boston Scientific
BSX
$65.3B
| $449M | 2.07% |
10,521,184
+3,050,500
| +41% | +$166M |
2020 Q3
23 quarters
|
|
16
Broadcom
AVGO
$1.6T
| $435M | 2.01% |
1,151,800
-627,700
| -35% | -$252M |
2025 Q4
2 quarters
|
|
|
17
Microsoft
MSFT
$3.96T
| $415M | 1.92% |
1,112,863
-1,231,916
| -53% | -$498M |
2013 Q3
51 quarters
|
|
18
Tango Therapeutics
TNGX
$3.97B
| $384M | 1.77% |
12,277,000
+3,179,589
| +35% | +$78.6M |
2024 Q4
6 quarters
|
|
19
KKR & Co
KKR
$78.1B
| $378M | 1.74% |
4,118,300
-553,500
| -12% | -$53.7M |
2025 Q4
2 quarters
|
|
20
Synopsys
SNPS
$87.1B
| $370M | 1.71% |
829,600
-383,700
| -32% | -$180M |
2025 Q4
2 quarters
|
|
21
Beam Therapeutics
BEAM
$2.5B
| $351M | 1.62% |
10,236,396
+101,700
| +1% | +$3.07M |
2021 Q1
21 quarters
|
|
22
DELISTED
Crinetics Pharmaceuticals
CRNX
| $336M | 1.55% |
8,989,098
+651,000
| +8% | +$24.2M |
2023 Q3
11 quarters
|
|
23
GRAIL Inc
GRAL
$5.47B
| $284M | 1.31% |
4,161,584
+907,900
| +28% | +$53.5M |
2025 Q2
4 quarters
|
|
24
Wabtec
WAB
$48.4B
| $241M | 1.11% |
894,503
-714,900
| -44% | -$189M |
2017 Q1
37 quarters
|
|
|
25
Immunovant
IMVT
$5.7B
| $224M | 1.03% |
5,805,000
+4,259,000
| +275% | +$130M |
2024 Q2
8 quarters
|
|
Similar funds
Farallon Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Farallon Capital Management held 194 positions worth $21.7B, up 14% from $19.1B the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Farallon Capital Management withdrew a net $3.46B in Q2 2026, closing 105 positions and reducing 23 holdings. Its most notable exit was Charles Schwab, an estimated $372M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 55% of assets, up from 47% a quarter earlier, followed by Miscellaneous and Communication Services.
Against the trend, Farallon Capital Management opened a new position in Parabilis Medicines Inc worth $64.8M.
- Farallon Capital Management's largest Q2 2026 buy was Parabilis Medicines Inc: 2,368,200 shares worth $64.8M.
- Farallon Capital Management added most to Boston Scientific in Q2 2026, an estimated $166M increase.
- Farallon Capital Management's biggest Q2 2026 reduction was Microsoft, cutting an estimated $498M.
- Farallon Capital Management fully exited Charles Schwab in Q2 2026, selling an estimated $372M.
- Farallon Capital Management's ten largest holdings make up 62% of its $21.7B portfolio in Q2 2026.
- Farallon Capital Management opened 19 new positions and closed 105 in Q2 2026.
- Farallon Capital Management's portfolio value rose 14% quarter-over-quarter to $21.7B.
Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.